256492-46-3

Upstream product

• 42287-94-5 (4-cyanophenyl)propionic acid 

Downstream Products

• 256492-47-4 1-methyl-2-[2-(4-cyanophenyl)-ethyl]-5-amino-benzimidazole 
• 256493-28-4 1-methyl-2-[2-(4-cyanophenyl)-ethyl]-5-[N-(ethoxycarbonylmethyl)-quinoline-8-sulphonylamino]-benzimidazole 

Relevant academic research and scientific papers

Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions

Disclosed are carboxamide-substituted benzimidazole derivatives of general formula (I) wherein the groups X, R1, R2, R3 and R4 may have the meanings given in the claims and specification, processes for preparing

Arylysulphonamide-substituted benzimidazoles having tryptase-inhibiting activity

Arylsulphonamide-substituted benzimidazole derivatives of formula (I) having tryptase-inhibiting activity. Exemplary are: 1-Methyl-2-[2-(4-amidinophenyl)-ethyl]-5-[N-(2-diethylaminoethyl)-benzenesulphonylamino]-benzimidazole; 1-Methyl-2-[2-(4-amidinopheny

Arylsulphonamide-substituted benzimidazoles having tryptase-inhibiting activity

Bezimidazole derivatives of general formula (I) having tryptase-inhibitory activity. Exemplary are: N-{2-[2-(4-amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl}-N-diethylaminoethyl-(4-ethoxycarbonyl-benzenesulphonamide)-hydrochloride, N-{2-[2-(4-amidinoph

Carboxamide-substituted benzimidazoles having tryptase-inhibiting activity

The invention relates to carboxamide-substituted benzimidazole derivatives of general formula (I) wherein the groups R1, R2, R3and R4may have the meanings given in the claims and in the specification, processes for preparing them and the use of carboxamide-substituted benzimidazole derivatives as pharmaceutical compositions, particularly as pharmaceutical compositions with a tryptase-inhibiting effect.

Structure-based design of novel potent nonpeptide thrombin inhibitors

The clinical syndromes of thromboembolism are evoked by an excessive stimulation of the coagulation cascade. In this context, the serine protease thrombin plays a key role. Considerable efforts have therefore been devoted to the discovery of safe, orally active inhibitors of this enzyme. On the basis of the X-ray crystal structure of the peptidelike thrombin inhibitor NAPAP complexed with bovine thrombin, we have designed a new structural class of nonpeptidic inhibitors employing a 1,2,5-trisubstituted benzimidazole as the central scaffold. Supported by a series of X-ray structure analyses, we optimized the activity of these compounds. Thrombin inhibition in the lower nanomolar range could be achieved although the binding energy mainly results from nonpolar, hydrophobic interactions. To improve in vivo potency, we increased the overall hydrophilicity of the molecules by introducing carboxylate groups. The very polar compound 24 (BIBR 953) exhibited the most favorable activity profile in vivo. This zwitterionic molecule was converted into the double-prodrug 31 (BIBR 1048), which showed strong oral activity in different animal species. On the basis of these results, 31 was chosen for clinical development.

Disubstituted bicyclic heterocycles, the preparation thereof and their use as pharmaceutical compositions

Novel disubstituted bicyclic heterocycles, of which the following are exemplary: (a) 1-methyl-2-[(4-amidinophenyl)-oxymethyl]-5-[N-(hydroxycarbonylmethyl)-quinoline-8-sulphonylamino]-benzimidazole, (b) 1-methyl-2-[2-(4-amidinophenyl)-ethyl]-5-[N-(N-(hydroxycarbonylmethyl)-aminocarbonylmethyl)-quinoline-8-sulphonylamino]-benzimidazole, (c) 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-5-[N-(hydroxycarbonylmethyl)-quinoline-8-sulphonylamino]-benzimidazole and (d) 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-5-[N-(hydroxycarbonylmethyl)-quinoline-8-sulphonylamino]-indole. These are useful for the treatment of thrombotic disease.